Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary mvelodvsplastic syndromes

Journal of Clinical Oncology

Volumn 27, Issue 5, 2009, Pages 754-762

  Porta, Matteo Giovanni Delia ^a   Malcovati, Luca ^a   Boveri, Emanuela ^a   Travaglino, Erica ^a   Pietra, Daniela ^a   Pascutto, Cristiana ^a   Passamonti, Francesco ^a   Invernizzi, Rosangela ^a   Castello, Alessandro ^a   Magrini, Umberto ^a   Lazzarino, Mario ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; FEMALE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROSIS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 59949102794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.2246     Document Type: Article

References (30)

1. Bennett J M, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplas- tic syndromes. Br J Haematol 51:189-199, 1982
2. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
3. Cazzola M, Malcovati L: Myelodysplastic syndromes: Coping with ineffective hematopoiesis. N Engl J Med 352:536-538, 2005
4. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
5. Malcovati L, Della Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodys- plastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005
6. Germing U, Strupp C, Kuendgen A, et al: Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haema- tologica 91:1596-1604, 2006
7. Malcovati L, Della Porta MG, Cazzola M: Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91:1588-1590, 2006
8. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in my-elodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007
9. Tricot G, De Wolf-Peeters C, Vlietinck R, et al: Bone marrow histology in myelodysplastic syndromes: II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217-225, 1984
10. Ríos A, Canizo MC, Sanz MA, et al: Bone marrow biopsy in myelodysplastic syndromes: Morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 75:26-33, 1990
11. Oriani A, Annaloro C, Soligo D, et al: Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodys- plastic syndromes. Br J Haematol 92:360-364,1996
12. Verburgh E, Achten R, Maes B, et al: Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodys-plastic syndromes. J Clin Oncol 21:273-282, 2003
13. Mangi M H, Mufti G J: Primary myelodysplastic syndromes: Diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79:198-205, 1992
14. Lambertenghi-Deliliers G, Orazi A, Luksch R, et al: Myelodysplastic syndrome with increased marrow fibrosis: A distinct clinico-pathological entity. Br J Haematol 78:161-166, 1991
15. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al: Myelodysplastic syndromes with bone marrow fibrosis: A myelodysplastic disorder with prolifera-tive features. Ann Hematol 63:235-241, 1991
16. Maschek H, Georgii A, Kaloutsi V, et al: My-elofibrosis in primary myelodysplastic syndromes: A retrospective study of 352 patients. Eur J Haematol 48:208-214, 1992
17. Maschek H, Gutzmer R, Choritz H, et al: Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haema- tol 53:280-287, 1994
18. Buesche G, Teoman H, Wilczak W, et al: Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313-322, 2008
19. Thiele J, Kvasnicka HM, Facchetti F, et al: European consensus on grading bone marrow fibro- sis and assessment of cellularity. Haematologica 90:1 128-1 132, 2005
20. Boveri E, Passamonti F, Rumi E, et al: Bone marrow microvessel density in chronic myelopro- liferative disorders: A study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 140:162-168, 2008
21. Thiele J, Arenz B, Klein H, et al: Differentiation of plasma cell infiltrates in the bone marrow: A clinicopathological study on 80 patients including immunohistochemistry and morphometry. Vir-chows Arch A Pathol Anat Histopathol 412:553-562, 1988
22. Passamonti F, Rumi E, Pietra D, et al: Relation between JAK2 (V617F) mutation status, gran- ulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloprolif- erative disorders. Blood 107:3676-3682, 2006
23. Tefferi A, Thiele J, Orazi A, et al: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary my- elofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097,2007
24. Bowen D, Culligan D, Jowitt S, et al: Guidelines for the diagnosis and therapy of adult myelo- dysplastic syndromes. Br J Haematol 120:187-200, 2003
25. Soligo DA, Oriani A, Annaloro C, et al: CD34 immunohistochemistry of bone marrow biopsies:Prognostic significance in primary myelodysplas- tic syndromes. Am J Hematol 46:9-17, 1994
26. Lambertenghi Deliliers G, Annaloro C, So- ligo D, et al: The diagnostic and prognostic value of bone marrow immunostaining in myelodysplas- tic syndromes. Leuk Lymphoma 28:231-239, 1998
27. Barosi G, Bergamaschi G, Marchetti M, et al: JAK2 V617F mutational status predicts progressionto large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110:4030-4036, 2007
28. Kremer M, Horn T, Dechow T, et al: The JAK2 V617F mutation occurs frequently in myelo- dysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia 20:1315-1316, 2006
29. Malcovati L, Cazzola M: Myelodysplastic/my- eloproliferative disorders. Haematologica 93:4-6, 2008
30. Schmitt-Graeff AH, Teo SS, Olschewski M, et al: JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sider- oblasts associated with marked thrombocytosis. Haematologica 93:34-40, 2008